Active secondary progressive MS is defined as people experiencing relapses or showing signs of inflammation in MRI scans
This is exciting news, as siponimod is the first oral drug to be licensed for secondary progressive MS in Europe. Secondary progressive MS has an impact on all aspects of people’s lives – physical, emotional, social and economic - affecting not only the person diagnosed, but also their families. We hope that the availability of a new treatment will lead to a renewed focus on the needs of all people with progressive MS and improve their access to services.
- David Martin, Chief Executive Officer, MS Trust
As someone with SPMS I am delighted that at last a treatment has been licensed for people like myself. For too long we have been excluded from services and been ignored, this decision provides an opportunity to slow our disease progression with the possibility of improving our quality of life immeasurably. Roll on NICE approval.
- Caroline Smith
The next step in the approval process is for the European Commission to grant the licence, taking into the consideration the EMA's recommendation. Siponimod will then be appraised by NICE and SMC to decide whether it is a cost-effective treatment for the NHS.
NICE has already started the appraisal process for siponimod and a decision is expected in May 2020. The MS Trust is responded to the appraisal. If NICE approves the use of siponimod, it could be available on the NHS by the end of 2020.
Siponimod is taken as a tablet, once a day.
In clinical trials for secondary progressive MS, siponimod reduced the risk of disability progression by 26% compared to placebo. Further analysis indicated a 37% reduction in the risk of progression for those with active SPMS (defined as those who had relapsed in the two years prior to starting the trial).
In clinical trials, low white blood cell count, increased liver enzyme levels, slower heart rate when starting treatment, macular oedema (swelling in the back of the eye affecting vision), high blood pressure, shingles, and convulsions occurred more frequently with siponimod than with placebo.
Pain, fatigue, depression and anxiety common in first year after multiple sclerosis diagnosis
21/07/2022 - 00:00
Pain, fatigue, depression and anxiety are common in established MS; this study monitored the symptoms during the first year after diagnosis of MS.
Updated NICE multiple sclerosis guideline contains some good news and some bad news
22/06/2022 - 00:00
There are some positive points in the revised 2022 guideline but the MS Trust is disappointed that NICE has been unable to recommend Fampyra.
The ADAMS project
25/05/2022 - 00:00
Dr Benjamin Jacobs spoke to us about a new study on the genetics of MS in people from minority ethnic backgrounds which may eventually shed light on why MS can be more severe for Black and Asian people.
How being Asian has affected my experience of living with multiple sclerosis
04/08/2022 - 00:00
Health and disability advocate, Trishna Bharadia, blogs about her experiences of MS and the reaction her diagnosis has received from other members of the South Asian community.
Five minutes with a fundraiser: Huxley's Miles for MS
20/07/2022 - 00:00
In May 2022, eight-year-old Huxley was inspired to take on his first Miles for MS challenge. Here, Huxley tells us all about his motivation and how he ended up creating a song from the experience!
When is a relapse not a relapse?
20/07/2022 - 00:00
Have you ever been told you’re having a pseudo relapse? In this blog Helena from the MS Trust info and engagement team looks into some different situations, when a relapse perhaps isn't a relapse after all.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.